Prostate cancer antigen 3 test for prostate biopsy decision: A systematic review and meta analysis

Chinese Medical Journal

Volumn 127, Issue 9, 2014, Pages 1768-1774

  Yong, Luo ^a   Xin, Gou ^a   Peng, Huang ^a   Chan, Mou ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Early detection; Prostate cancer; Prostate cancer antigen 3

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; BIBLIOGRAPHIC DATABASE; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE OVEREXPRESSION; GOLD STANDARD; HUMAN; INFORMATION PROCESSING; MALE; META ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER ANTIGEN 3 TEST; QUALITY CONTROL; QUESTIONNAIRE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; URINALYSIS; BIOPSY; METABOLISM; PROSTATIC NEOPLASMS;

ANTIGENS, NEOPLASM; BIOPSY; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84899750574     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20132519     Document Type: Article

References (46)

1. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. JAMA 1997; 277: 1452-1455.
2. Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001; 165: 757-760.
3. Roehl KA, Antenor JAV, Catalona WJ. Serial biopsy results in prostate cancer screening study. J Urol 2002; 167: 2435-2439.
4. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64: 311-315.
5. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.
6. Freedland SJ, Partin AW. Detecting prostate cancer with molecular markers: uPM3. Rev Urol 2005; 7: 236-238.
7. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52: 1089-1095.
8. Overmyer M. New PCA assay aids critical diagnostic decisions. Urology Times. July 1, 2006.
9. Marks LS, Fradet Y, Lim Deras I, Blase A, Mathis J, Aubin SM, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69: 532-535.
10. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.
11. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
12. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079-1092.
13. Van Gils MPMQ, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PFA, et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 2007; 67: 881-887.
14. Van Gils MPMQ, Hessels D, Van Hooij O, Jannink SA, Peelen WP, Hanssen SLJ, et al. Validation of the PCA3 urine test in a multicenter study in the Netherlands. Ned Tijdschr Geneeskd 2007; 15: 49-53.
15. Van Gils MPMQ, Hessels D, Van Hooij O, Jannink SA, Peelen WP, Hanssen SLJ, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 2007; 13: 939-943.
16. Deras IL, Aubin SMJ, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179: 1587-1592.
17. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, et al. Clinical utility of the PCA3 urine assay in european men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-1088.
18. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008; 179: 1804-1809.
19. Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM. A duplex quantitative polymerase chain reaction assay based on quantification of (alpha)-methylacyl-coa racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol 2009; 181: 2508-2514.
20. Shappell SB, Fulmer J, Arguello D, Wright BS, Oppenheimer JR, Putzi MJ. PCA3 Urine mRNA testing for prostate carcinoma: patterns of use by community urologists and assay performance in reference laboratory setting. Urology 2009; 73: 363-368.
21. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009; 115: 3879-3886.
22. Auprich M, Haese A, Walz J, Pummer K, De La Taille A, Graefen M, et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 2010; 58: 727-732.
23. Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate 2010; 70: 1760-1767.
24. Roobol MJ, Schroder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010; 58: 475-481.
25. De La Taille A, Irani J, Graefen M, Chun F, De Reijke T, Kil P, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011; 185: 2119-2125.
26. Ochiai A, Okihara K, Kamoi K, Iwata T, Kawauchi A, Miki T, et al. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy. Int J Urol 2011; 18: 200-205.
27. Vlaeminck-Guillem V, Campos-Fernandes JL, Champetier D, Chikh K, Decaussin-Petrucci M, Devonec M, et al. Value of PCA3 urinary test for prostate biopsy decision: the lyon-sud university hospital experience. Ann Biol Clin (Paris) 2011; 69: 31-39.
28. Crawford ED, Rove KO, Trabulsi EJ, Qian JQ, Drewnowska KP, Kaminetsky JC, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 2012; 188: 1726-1731.
29. Ng CF, Chiu PKF, Lam NY, Yeung R, Chow J, Chan B. The role of urine prostate cancer antigen 3 mrna levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med J 2012; 18: 459-465.
30. Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama SI, et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int 2013; 111: 928-933.
31. Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a polish cohort. Anticancer Res 2013; 33: 553-558.
32. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine: a new perspective for detecting prostate cancer. Eur Urol 2004; 46: 182-186.
33. Hessels D, Gunnewiek J, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44: 8-15.
34. Galasso F, Giannella R, Bruni P, Giulivo R, Barbini VR, Disanto V, et al. PCA3: a new tool to diagnose prostate cancer (PCa) and a guidance in biopsy decisions. Preliminary report of the UrOP study. Arch Ital Urol Androl 2010; 82: 5-9.
35. Herness EA, Naz RK. A novel human prostate-specific Gene-1 (HPG-1) molecular cloning, sequencing, and its potential involvement in prostate carcinogenesis. Cancer Res 2003; 63: 329-336.
36. Jiang Z, Wu C, Woda B, Iczkowski K, Chu P, Tretiakova M, et al. Alpha©\methylacyl CoA racemase: a multiinstitutional study of a new prostate cancer marker. Histopathology 2004; 45: 218-225.
37. Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F. Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J Biol Chem 2002; 277: 36689-36696.
38. Korkmaz CG, Korkmaz KS, Kurys P, Elbi C, Wang L, Klokk TI, et al. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 2005; 24: 4934-4945.
39. Tsavaler L, Shapero MH, Morkowski S, Laus R. Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res 2001; 61: 3760-3769.
40. Murata M, Watanabe M, Yamanaka M, Kubota Y, Ito H, Nagao M, et al. Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and GSTT1 and susceptibility to prostate cancer in the Japanese population. Cancer Lett 2001; 165: 171-177.
41. Ruscica M, Dozio E, Boghossian S, Bovo G, Riaño VM, Motta M, et al. Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. Endocrinology 2006; 147: 1466-1473.
42. Zhang YF, Guan YB, Yang B, Wu HY, Dai YT, Zhang SJ, et al. Prognostic value of Her-2/neu and clinicopathologic factors for evaluating progression and disease-specific death in Chinese men with prostate cancer. Chin Med J 2011; 124: 4345-4349.
43. He HC, Bi XC, Dai QS, Wang SS, Wei HA, Zhong WD, et al. Detection of pim-1 mRNA in prostate cancer diagnosis. Chin Med J 2007; 120: 1491-1493.
44. Tricoli JV, Schoenfeldt M, Conley BA. Detection of prostate cancer and predicting progression current and future diagnostic markers. Clin Cancer Res 2004; 10: 3943-3953.
45. Klecka J, Holubec L, Pesta M, Topolcan O, Hora M, Eret V, et al. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. Anticancer Res 2010; 30: 665-670.
46. Aubin SMJ, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010; 184: 1947-1952.